Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC
Status:
RECRUITING
Trial end date:
2029-06-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, phase 2 study to investigate the efficacy and safety of sunvozertinib as neoadjuvant and adjuvant treatment for stage II-IIIB non-small-cell lung cancer patients with EGFR exon20 insertion mutation.